乳海藻糖:抗海藻糖酶类似物可增强小鼠能量代谢而不促进艰难梭菌感染
本研究通过细胞和小鼠实验比较乳海藻糖与海藻糖的代谢效应及对艰难梭菌的影响。乳海藻糖抵抗海藻糖酶,在HEK293细胞中阻断葡萄糖转运,并在原代肝细胞中诱导禁食相关基因表达。高果糖饮食小鼠中,乳海藻糖未出现肝脂肪变性等代谢异常,且不增加艰难梭菌CD027的丰度或毒性。
要点
- 乳海藻糖抵抗海藻糖酶,可避免被分解为单糖。
- 乳海藻糖在高果糖饮食小鼠中减少肝脂肪变性和胆固醇。
- 乳海藻糖不增加艰难梭菌CD027的丰度或毒素水平。
核心结论
- 乳海藻糖是一种抗海藻糖酶类似物,与海藻糖相比可改善代谢参数而不增加艰难梭菌CD027的丰度或毒力。
研究设计与样本
- 研究使用HEK293和Caco2细胞、小鼠原代肝细胞及人肠道类器官。
- C57B6/J小鼠接受口服抗生素后饮用海藻糖或乳海藻糖水,随后灌胃艰难梭菌CD027。
- 另一部分小鼠饮用海藻糖或乳海藻糖2天后给予60%果糖饮食10天。
主要发现
- 乳海藻糖和海藻糖在HEK293细胞中均阻断葡萄糖转运,并在原代肝细胞中诱导禁食相关基因表达。
- 高果糖饮食小鼠中,乳海藻糖组未出现循环胆固醇升高、肝重/体重比增加、肝脂肪变性及碳水化合物反应性新生脂肪生成基因表达。
- 乳海藻糖组小鼠全身热量消耗增加,肝脏线粒体能量代谢基因转录增加。
- 乳海藻糖在门静脉和体循环及粪便中可检测到,并降低粪便微生物支链氨基酸合成标志物、增加胰岛素信号相关微生物基因表达。
- 在CD027感染小鼠中,乳海藻糖和海藻糖均未增加粪便中细菌或毒素水平,海藻糖反而降低CD027丰度,两者均减少直肠组织炎症标志物。
临床怎么用
- 乳海藻糖可能作为下一代禁食模拟剂用于糖尿病和非酒精性脂肪肝病的治疗。
局限性
- 研究仅在小鼠模型中进行,尚未在人体中验证。
- 实验使用特定艰难梭菌核糖体型CD027,其他菌株的影响未知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Trehalose is a disaccharide that might be used in the treatment of cardiometabolic diseases. However, trehalose consumption promotes the expansion of Clostridioides difficile ribotypes that metabolize trehalose via trehalose-6-phosphate hydrolase. Furthermore, brush border and renal trehalases can reduce the efficacy of trehalose by cleaving it into monosaccharides. We investigated whether a trehalase-resistant analogue of trehalose (lactotrehalose) has the same metabolic effects of trehalose without expanding C difficile. METHODS: We performed studies with HEK293 and Caco2 cells, primary hepatocytes from mice, and human intestinal organoids. Glucose transporters were overexpressed in HEK293 cells, and glucose tra2nsport was quantified. Primary hepatocytes were cultured with or without trehalose or lactotrehalose, and gene expression patterns were analyzed. C57B6/J mice were given oral antibiotics and trehalose or lactotrehalose in drinking water, or only water (control), followed by gavage with the virulent C difficile ribotype 027 (CD027); fecal samples were analyzed for toxins A (ToxA) or B (ToxB) by enzyme-linked immunosorbent assay. Other mice were given trehalose or lactotrehalose in drinking water for 2 days before placement on a chow or 60% fructose diet for 10 days. Liver tissues were collected and analyzed by histologic, serum biochemical, RNA sequencing, autophagic flux, and thermogenesis analyses. We quantified portal trehalose and lactotrehalose bioavailability by gas chromatography mass spectrometry. Fecal microbiomes were analyzed by 16S ribosomal RNA sequencing and principal component analyses. RESULTS: Lactotrehalose and trehalose each blocked glucose transport in HEK293 cells and induced a gene expression pattern associated with fasting in primary hepatocytes. Compared with mice on the chow diet, mice on the high-fructose diet had increased circulating cholesterol, higher ratios of liver weight-to-body weight, hepatic lipid accumulation (steatosis), and liver gene expression patterns of carbohydrate-responsive de novo lipogenesis. Mice given lactotrehalose while on the high-fructose diet did not develop any of these features and had increased whole-body caloric expenditure compared with mice given trehalose or water and fed a high-fructose diet. Livers from mice given lactotrehalose had increased transcription of genes that regulate mitochondrial energy metabolism compared with liver from mice given trehalose or controls. Lactotrehalose was bioavailable in venous and portal circulation and fecal samples. Lactotrehalose reduced fecal markers of microbial branched-chain amino acid biosynthesis and increased expression of microbial genes that regulate insulin signaling. In mice given antibiotics followed by CD027, neither lactotrehalose nor trehalose increased levels of the bacteria or its toxin in stool-in fact, trehalose reduced the abundance of CD027 in stool. Lactotrehalose and trehalose reduced markers of inflammation in rectal tissue after CD027 infection. CONCLUSIONS: Lactotrehalose is a trehalase-resistant analogue that increases metabolic parameters, compared with trehalose, without increasing the abundance or virulence of C difficile strain CD027. Trehalase-resistant trehalose analogues might be developed as next-generation fasting-mimetics for the treatment of diabetes and nonalcoholic fatty liver disease.
引用
- Zhang Y, Shaikh N, Ferey JL, et al. Lactotrehalose, an Analog of Trehalose, Increases Energy Metabolism Without Promoting Clostridioides difficile Infection in Mice. Gastroenterology. 2019. PMID: 31838076. doi:10.1053/j.gastro.2019.11.295
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。